Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Home/The Filing Wire/Aptose Biosciences, Inc./ 8-K

Current Report · Items 7.01, 9.01 · 8-K

Aptose Biosciences, Inc.

Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. On May 29, 2026, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.…

Filed May 29, 2026Accepted May 29, 2026, 7:40 AM EDTCIK 882361Accession 0001171843-26-003778
View company →Permanent SEC source ↗
Share

Company context

Aptose Biosciences Inc. (“Aptose,” the “Company,” “we,” “us,” or “our”) is a science-driven clinical stage biotechnology company committed to the development and commercialization of precision medicines addressing unmet clinical needs in oncology, with an initial focus on hematology. The Company’s small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company’s executive offices are located in San Diego, California, and our head office is located in Toronto, Canada.

Current securities

APTOFOTC · EQUITY · Current
Historical securities (1)
APSTSX · EQUITY · Historical · closed Jul 2, 2026

Recent company filings

  1. 15-12G filingJul 1, 2026
  2. SC 13E3/A filingJul 1, 2026
  3. Completion of Acquisition or Disposition of Assets · Material Modification to Rights of Security Holders · Changes in Control of Registrant · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Other EventsJul 1, 2026
  4. Regulation FD DisclosureJul 1, 2026
  5. Regulation FD DisclosureJun 15, 2026

Disclosure sections

Items 7.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 7.01Item 7.01 - Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On May 29, 2026, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in the press release attached as Exhibit 99.1 hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.